TAK, US8740602052

Takeda Pharmaceutical stock trades at 53.16 times earnings

Published on 10/13/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda's second-quarter report is due October 29, 2026. Takeda Pharmaceutical stock costs EUR 16.55 on October 13, 2026, up 2.05 percent on Tokyo.

Takeda's trailing multiple stood at 53.16 times earnings as of October 12, 2026.
The Tokyo listing was last at JPY 5,963 on October 13, 2026, up 2.05 percent.
Takeda Pharmaceutical stock costs EUR 16.55 at Lang & Schwarz on October 13, 2026 at 1:04 p.m. CEST, up 2.05 percent on Tokyo.
The company plans to release its second-quarter fiscal 2026 results on October 29, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical (ISIN US8740602052) traded at 53.16 times earnings as of October 12, 2026, a valuation figure that puts the stock's earnings multiple at the center of the market report. The Tokyo listing was last at JPY 5,963 on October 13, 2026 at 3:30 p.m. JST, up 2.05 percent from JPY 5,843. At Lang & Schwarz, Takeda Pharmaceutical stock was trading at EUR 16.55 on October 13, 2026 at 1:04 p.m. CEST.

Tokyo price rose 2.05 percent

The home-market session provides the clearest same-day comparison: Takeda gained 2.05 percent from JPY 5,843 to JPY 5,963. That move was stronger than the 0.50 percent increase recorded by Daiichi Sankyo and below the 2.36 percent rise at Astellas Pharma on the same Tokyo session.

Takeda's Tokyo price sat EUR 70.00 equivalent below its 52-week high of JPY 6,033 when measured in the quoted home currency, while the 52-week low was JPY 4,102. The session volume reached 4,001,400 shares against an average of 4,165,200, placing turnover at 96.07 percent of its average.

Valuation stays above peers

Takeda's 53.16 times earnings multiple was materially above Astellas Pharma's 11.33 and Daiichi Sankyo's 19.97. Its market capitalization was USD 59.4 billion as of October 12, 2026, compared with USD 26.0 billion for Astellas Pharma and USD 30.3 billion for Daiichi Sankyo.

The dividend yield was 0.03 percent for Takeda, Astellas Pharma and Daiichi Sankyo in the same quote snapshot. For investors, the contrast is between Takeda's larger valuation multiple and its smaller stated yield, while the Tokyo price remained 1.16 percent below its 52-week high.

October 29 report date

Takeda's next scheduled reporting event is the second-quarter fiscal 2026 earnings announcement on October 29, 2026. Takeda says the information will be released that day, with an investor webcast scheduled from 7:00 p.m. to 8:15 p.m. JST.

Comparison with peers

Takeda (NYSE, USD): plus 2.05 percent, 53.16 times earnings, market capitalization USD 59.4 billion

Astellas Pharma (Tokyo Stock Exchange, JPY): plus 2.36 percent, 11.33 times earnings, market capitalization JPY 4.1 trillion

Daiichi Sankyo (Tokyo Stock Exchange, JPY): plus 0.50 percent, 19.97 times earnings, market capitalization JPY 4.8 trillion

EUR 16.55 at Lang & Schwarz

Takeda Pharmaceutical stock was trading at EUR 16.55 at Lang & Schwarz on October 13, 2026 at 1:04 p.m. CEST. The Tokyo listing was last at JPY 5,963 at 3:30 p.m. JST, up 2.05 percent on the day. The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.